JP Morgan Cazenove Maintains Shire PLC (LON:SHP) As a “Overweight”; They Now Have a TP Of GBX 6100.00


Shire PLC (LON:SHP) Rating Reaffirmed

JP Morgan Cazenove now has a GBX 6100.00 target price on shares of Shire PLC (LON:SHP). The target price implies a potential upside of 30.48% from the price per share of Shire PLC (LON:SHP). This rating was disclosed to clients in a note on Friday morning.

From a total of 11 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 99.53 while the lowest target price is GBX 81.43. The mean of all analyst targets is GBX 90.22 with a 20.32% above today’s (GBX 4524) stock price. Shire PLC was the topic of 78 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on November 30 with “Outperform” rating. Barclays Capital maintained shares with “Overweight” rating and GBX 5700 target share price in a report from a November 3. JP Morgan maintained SHP stock in a recent report from November 17 with “Overweight” rating. Kepler Cheuvreux maintained the rating on November 3. Kepler Cheuvreux has a “Buy” rating and a GBX 5900 price target on shares. Finally, Credit Suisse maintained the stock with “Neutral” rating in a report issued on a November 4.

Approximately 9,052 shares of stock traded hands. Shire PLC (LON:SHP) has declined 12.48% since May 7, 2015 and is downtrending. It has underperformed by 9.70% the S&P500.

JP Morgan Cazenove Maintains Shire PLC (LON:SHP) As a

Shire plc is a biopharmaceutical company. The company has a market cap of 26.22 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.31 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.